Optima to host post-conference workshop at Lyophilization USA

SMi Group23 - 24 October 2019, Boston, USA.
Delegates for the 5th Annual Lyophilization USA conference, taking place in Boston, will have the opportunity to attend the half-day post-conference workshop titled "Current and Future Freeze-Drying Technologies and Methods" led by Dena Flamm and Alexander Tambovzev on October 25th 2019.

Overview of the workshop

Freeze dried products are well established in the market with an increasing trend in aseptically produced lyophilized products, including peptides and proteins. This workshop will give delegates an introduction into the Physics and Thermodynamics of Freeze-Drying; including both presentation of topics and an open discussion within the group. The session will support a better understanding of the Freeze-Drying process with the different methods available in the marketas well as discuss an alternative Freeze-Drying process for consideration.

Benefits of Attending

Delegates will have the opportunity to engage in an in-depth discussion with industry experts from Optima on the latest technological developments in the Lyophilization industry. They will also gain a better understanding of the most up to date freeze-drying technology available on the market, as well as what the future of this field looks like.

This workshop will enhance delegate's knowledge on controlled nucleation, available PAT's and the future of flexible PAT processes, and alternative freeze-drying technologies including spray drying, spin freeze-drying and microwave drying.

The brochure with the full conference program and workshop information is available to download online at http://www.lyophilisation-usa.com/PR3

Workshop Leader Overview

Dena Flamm is a Business Development Manager for OptimaMachinery Corporation. She is responsible for freeze dryer development in the North American market and has over 17 years of experience in the pharmaceutical industry. Studies include, an MBA in International Management from the University of St. Thomas with an undergraduate degree in Business and Physics.

Alexander Tambovzev is a Project Engineering and Development Group Leader at Optima Pharma, Germany. The area of his responsibility is leading the project engineering of the freeze dryers as well as the R&D effort in the freeze dryer technology. In 2008, Alexander received a Ph.D. in refrigeration technology from the Technical University of Dresden with a focus on the modelling of dynamic processes. He has worked in the research and development area of refrigeration systems for commercial and industrial applications.

An early bird saving of $200 is available for bookings placed before the 30th August. Registrations can be made online at http://www.lyophilisation-usa.com/PR3

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Intermittent fasting: live 'fast,' live longer?

For many people, the New Year is a time to adopt new habits as a renewed commitment to personal health. Newly enthusiastic fitness buffs pack into gyms and grocery stores...

Pharmacies leave customers hanging when it comes t…

Proper disposal of leftover medication, particularly antibiotics and opioids, can help reduce antibiotic resistance, prevent children from being poisoned and stop the mis...

Scientists find a new use for already known anti-c…

The world scientific community is waging a difficult and prolonged war on cancer. New research in the field of immunogenic cell death can extend the area of drugs applica...

Bayer and Exscientia collaborate to leverage the p…

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners...

Researchers determine how a specific protein regul…

Immune checkpoints are surface proteins that cancer cells use to evade immune response. These surface proteins are critical for cancer cell growth and drugs targeting the...

Bristol-Myers Squibb completes divestment of manuf…

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufa...

Lynparza approved in the US as a 1st-line maintena…

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US f...

FDA approves first generics of Eliquis

The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolis...

Farxiga granted FDA Priority Review for patients w…

AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dap...

Aspirin appears to curb colorectal cancer recurren…

The benefits of a daily aspirin may extend beyond heart health to colorectal cancer treatment, say City of Hope researchers who have found aspirin appears to reduce tumor...

Plant-derived SVC112 hits cancer stem cells, leave…

The red, tube-shaped flowers of the firecracker bush (Bouvardia ternifolia), native to Mexico and the American Southwest, attract hummingbirds. The bush also provides the...

Amgen announces global diagnostic collaborations

Amgen (NASDAQ: AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based c...